Stock Events

Stock Events

Eupraxia Pharmaceuticals 

€5.6
0
-€0.15-2.61% Friday 19:47

Statistics

Day High
5.95
Day Low
5.55
52W High
7.5
52W Low
2.44
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q4 2025
Next
-0.27
-0.22
-0.18
-0.13
Expected EPS
-0.161985210513984
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow X43.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie competes in the pharmaceuticals sector, focusing on immunology and oncology, areas Eupraxia also targets with its drug development.
Pfizer
PFE
Mkt Cap161.09B
Pfizer is a global biopharmaceutical company with a broad range of products in various therapeutic areas, overlapping with Eupraxia's focus.
Merck
MRK
Mkt Cap298.84B
Merck operates in the pharmaceuticals industry, developing drugs that could directly compete with Eupraxia's pipeline in areas like inflammation and pain management.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson, through its pharmaceutical segment, competes across various therapeutic areas, including those being targeted by Eupraxia.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb offers a wide range of pharmaceutical products, potentially competing with Eupraxia in the development of treatments for chronic conditions.
Novartis
NVS
Mkt Cap297.32B
Novartis is a global healthcare company that operates in similar therapeutic areas as Eupraxia, making it a direct competitor in drug development.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences focuses on areas like inflammation and oncology, directly competing with Eupraxia's research and development efforts.
AMGEN
AMGN
Mkt Cap187.56B
Amgen specializes in biopharmaceuticals, with a product lineup that could compete with Eupraxia's treatments in development.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals is involved in biopharmaceuticals, focusing on innovative treatments that could rival Eupraxia's pipeline.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals engages in creating new therapies for treating chronic diseases, a field where Eupraxia is also aiming to innovate.

About

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Show more...
CEO
Dr. James A. Helliwell FRCPC, M.D.
Employees
49
Country
CA
ISIN
CA29842P1053

Listings

F
DE
X43.F
STU
DE
X43.STU
TO
CA
EPRX.TO
XNAS
US
EPRX

0 Comments

Share your thoughts

FAQ

What is Eupraxia Pharmaceuticals stock price today?▼
The current price of X43.STU is €5.6 EUR — it has decreased by -2.61% in the past 24 hours. Watch Eupraxia Pharmaceuticals stock price performance more closely on the chart.
What is Eupraxia Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Eupraxia Pharmaceuticals stocks are traded under the ticker X43.STU.
Is Eupraxia Pharmaceuticals stock price growing?▼
X43.STU stock has fallen by -4.27% compared to the previous week, the month change is a -12.5% fall, over the last year Eupraxia Pharmaceuticals has showed a +117.05% increase.
When is the next Eupraxia Pharmaceuticals earnings date?▼
Eupraxia Pharmaceuticals is going to release the next earnings report on May 07, 2026.
What were Eupraxia Pharmaceuticals earnings last quarter?▼
X43.STU earnings for the last quarter are -0.27 EUR per share, whereas the estimation was -0.13 EUR resulting in a -103.85% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Eupraxia Pharmaceuticals have?▼
As of April 11, 2026, the company has 49 employees.
In which sector is Eupraxia Pharmaceuticals located?▼
Eupraxia Pharmaceuticals operates in the Health Care sector.
When did Eupraxia Pharmaceuticals complete a stock split?▼
Eupraxia Pharmaceuticals has not had any recent stock splits.
Where is Eupraxia Pharmaceuticals headquartered?▼
Eupraxia Pharmaceuticals is headquartered in Victoria, CA.